Accelerate your MedTech innovation with CPI – UK expertise for US companies
From breakthrough to market – faster, safer, and smarter.
CPI is an independent deep-tech innovation centre with more than 20 years of experience helping companies bring transformative MedTech solutions to life. We partner with UK, US and Global innovators to develop, prove, scale-up, and commercialise products in patient monitoring, in-vitro diagnostics (IVD), and drug-delivery devices.
Why US MedTech companies choose CPI
Speed to market
From defining user needs to full-scale production, CPI’s end-to-end capabilities and $300M in cutting-edge facilities mean you can advance without the delays of building infrastructure.
De-risk your development
Our 500+ scientists and engineers provide multidisciplinary expertise across materials, formulation, digital & software, fabrication, testing, and regulatory; ensuring your product is technically and commercially ready.
Maximise your investment
Leverage CPI’s facilities, expertise, and UK government backing to reduce capital expenditure, access strategic networks, and secure funding.
Regulatory confidence
Navigate FDA, CE, and UKCA requirements with our regulatory specialists, streamlining approval while you focus on innovation.
Our Expertise
IVD
From technology definition to scale-up, including assay development, lateral flow, and advanced biosensors.
Patient monitoring
Non-invasive and minimally invasive wearable devices, flexible electronics, and wearable solutions.
Drug delivery devices
Advanced wound healing, drug delivery systems, and novel therapeutic formats.
MedTech regulatory support
Product development with regulatory expertise and guidance for seamless compliance with global healthcare standards.
Proven impact – Real US-relevant success stories
MIT
CPI regularly hosts MIT placement students in its facilities in the UK. They work alongside CPI’s team in medtech, formulations, and biotechnology, providing real impact to the global companies we support.
Calysta
CPI helped Calysta develop and scale up a gas fermentation process that converts carbon gases into a sustainable protein for aquaculture. CPI advanced from early development to producing tonnes of material at its facilities in the UK.
CEPI and Caltech
CPI leads the engineering biology process development of the novel MOSAIC‑8 vaccine, which was developed at Caltech and enables protection against SARS-CoV‑2 variants and other Betacoronaviruses. The vaccine is now in phase I clinical trials.
Alnylam Labs
Partnering with CPI to develop a manufacturing centre for oligonucleotide therapeutics that use novel manufacturing processes such as liquid phase and enzymatic.
Why choose CPI?
CPI has also worked with a whole host of US based clients under strict confidentiality with projects relating to IVD, materials, biotechnology and bioengineering broadly across the pharma, medtech and materials sectors.
Our cross discipline expertise is world renowned and if you’re innovating at the cutting edge of medtech and need support in strategy, product development, prototyping or scale up and want to move more quickly – talk to us and lets see how our capabilities can augment yours.
For more information
Let’s innovate together
To find out more about how we can work together, please enter your details below.